Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo

Circulation Research

Volumn 104, Issue 6, 2009, Pages 750-757

  Marsche, Gunther ^a   Frank, Sasa ^b   Hrzenjak, Andelko ^c   Holzer, Michael ^a   Dirnberger, Sabine ^a   Wadsack, Christian ^d   Scharnagl, Hubert ^e   Stojakovic, Tatjana ^e   Heinemann, Akos ^a   Oettl, Karl ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Institute of Medical Biochemistry and Medical Molecular Biology   (Austria)

^c Department of Pathology ^*  (Austria)

^d Univ Clin of Obstet and Gynecol   (Austria)

^e Clinical Institute of Medical   (Austria)

Author keywords

AOPP; HDL; Hemodialysis; Myeloperoxidase; Oxidative stress

Indexed keywords

ADENOVIRUS VECTOR; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN RECEPTOR; IODINE 125; SCAVENGER RECEPTOR BI; ALBUMINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SCARB1 PROTEIN, HUMAN; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B;

AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HEMODIALYSIS; IN VIVO STUDY; KIDNEY DISEASE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; CHO CELL; CHRONIC KIDNEY FAILURE; CRICETULUS; DRUG ANTAGONISM; GENETICS; HALF LIFE TIME; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN BINDING; PROTEIN CARBONYLATION; RISK FACTOR;

ALBUMINS; ANIMALS; CARDIOVASCULAR DISEASES; CHO CELLS; CHOLESTEROL, HDL; CRICETINAE; CRICETULUS; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MICE; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN CARBONYLATION; RISK FACTORS; SCAVENGER RECEPTORS, CLASS B;

EID: 64249106724     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.193169     Document Type: Article

References (32)

1. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
2. Mayer B, Zitta S, Greilberger J, Holzer H, Reibnegger G, Hermetter A, Oettl K. Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta. 2003;1638:267-272.
3. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 2001;60:358-363.
4. Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta. 2004;1689:91-102.
5. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallström S, Lackner C, Stauber RE. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta. 2008;1782:469-473.
6. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, Descamps-Latscha B. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003;64:82-91.
7. Capeillere-Blandin C, Gausson V, Nguyen AT, Descamps-Latscha B, Drueke T, Witko-Sarsat V. Respective role of uremic toxins and myeloperoxidase in the uremic state. Nephrol Dial Transplant. 2006;21:1555-1563.
8. Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoproteindependent selective lipid uptake and reverse cholesterol transport. J Biol Chem. 2002;277:32172-32179.
9. Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, Malle E. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem. 2003;278: 47562-47570.
10. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
11. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev. 2003;24:357-387.
12. Fuh MM, Lee CM, Jeng CY, Shen DC, Shieh SM, Reaven GM, Chen YD. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int. 1990;37:1295-1300.
13. Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992;41:1653-1661.
14. Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1156-1162.
15. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290: 262-272.
16. Anderstam B, Ann-Christin BH, Valli A, Stenvinkel P, Lindholm B, Suliman ME. Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta. 2008;393: 114-118.
17. Marsche G, Weigle B, Sattler W, Malle E. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified lowdensity lipoprotein FASEB J. 2007;21:3075-3082.
18. Marsche G, Semlitsch M, Hammer A, Frank S, Weigle B, Demling N, Schmidt K, Windischhofer W, Waeg G, Sattler W, Malle E. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J. 2007;21:1145-1152.
19. Marsche G, Heller R, Fauler G, Kovacevic A, Nuszkowski A, Graier W, Sattler W, Malle E. 2-chlorohexadecanal derived from hypochloritemodified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol. 2004;24:2302-2306.
20. Marsche G, Frank S, Raynes JG, Kozarsky KF, Sattler W, Malle E. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J. 2007;402:117-124.
21. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, Horiuchi S, Nakayama H. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem. 2001;276:13348-13355.
22. Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, Murata T, Otagiri M. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta. 2007;1772:1192-1198.
23. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D, Kruijt JK, Sattler W, Tietge UJ, Ninio E, Van Berkel TJ, Pratico' D. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol. 2007;27:2413-2419.
24. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72:1149-1156.
25. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4: 193-205.
26. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870-2874.
27. Lindner A, Charra B, Sherrard DJ, Schribner BH. Accelerated atherosclerosis in prolonged maintenance haemodialysis. N Engl J Med. 1974; 290:697-701.
28. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 1997;51:1678-1695.
29. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005;45: 39-47.
30. Iwao Y, Nakajou K, Nagai R, Kitamura K, Anraku M, Maruyama T, Otagiri M. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol. 2008;295:1871-1880.
31. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2008;283:27255-27269.
32. Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D, Zhang X. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal. 2008;10:1699-1712.